This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Izencitinib
DrugBank Accession Number
DB16660
Background

Izencitinib is under investigation in clinical trial NCT03920254 (TD-1473 Long-term Safety (LTS) Ulcerative Colitis (UC) Study).

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 402.506
Monoisotopic: 402.228042869
Chemical Formula
C22H26N8
Synonyms
  • 3-((1r,3s,5s)-3-((7-((5-methyl-1h-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo(3.2.1)octan-8-yl)propanenitrile
  • 8-azabicyclo(3.2.1)octane-8-propanenitrile, 3-((7-((5-methyl-1h-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-, (3-exo)-
External IDs
  • TD-1473
  • TD1473
  • WHO 11132

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
2ZT81PV5UM
CAS number
2051918-33-1
InChI Key
DADAEARVGOQWHV-OSYLJGHBSA-N
InChI
InChI=1S/C22H26N8/c1-14-10-21(29-28-14)26-20-13-19-18(4-2-8-24-19)22(27-20)25-15-11-16-5-6-17(12-15)30(16)9-3-7-23/h2,4,8,10,13,15-17H,3,5-6,9,11-12H2,1H3,(H3,25,26,27,28,29)/t15-,16-,17+
IUPAC Name
3-[(1R,3S,5S)-3-({7-[(5-methyl-1H-pyrazol-3-yl)amino]-1,6-naphthyridin-5-yl}amino)-8-azabicyclo[3.2.1]octan-8-yl]propanenitrile
SMILES
CC1=CC(NC2=NC(N[C@H]3C[C@@H]4CC[C@H](C3)N4CCC#N)=C3C=CC=NC3=C2)=NN1

References

General References
Not Available
ChemSpider
75536963

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2RecruitingTreatmentCrohn's Disease (CD)1
2RecruitingTreatmentCrohn's Disease (CD) / Diabetic Gastroparesis1
2, 3Active Not RecruitingTreatmentUlcerative Colitis2
1CompletedBasic ScienceHealthy Subjects (HS)1
1CompletedBasic ScienceInflammatory Bowel Diseases (IBD)1
1CompletedBasic ScienceInflammatory Bowel Diseases (IBD) / Intestinal Disorders1
1CompletedTreatmentInflammatory Bowel Diseases (IBD)1
1CompletedTreatmentInflammatory Bowel Diseases (IBD) / Intestinal Disorders1
1CompletedTreatmentModerate Ulcerative colitis / Ulcerative Colitis, Active Severe1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.061 mg/mLALOGPS
logP3.87ALOGPS
logP2.44ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)13.25ChemAxon
pKa (Strongest Basic)7.3ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area105.55 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity118.38 m3·mol-1ChemAxon
Polarizability44.79 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at March 26, 2021 02:39 / Updated at March 26, 2021 03:55